The nucleus basalis of Meynert (NBM) is a critical basal forebrain structure containing large cholinergic neurons that provide the primary cholinergic innervation to the entire neocortex[1][2]. These neurons are essential for cortical activation, attention, learning, and memory formation. The NBM undergoes severe degeneration in Alzheimer's disease (AD), making it a central target for therapeutic interventions.
The NBM is a collection of approximately 200,000-600,000 large, magnocellular cholinergic neurons in the basal forebrain. Key characteristics:
The NBM spans several basal forebrain nuclei:
| Projection Type | Target Regions | Function |
|---|---|---|
| Diffuse | Whole cortex | Global arousal |
| Regional | Frontal/Temporal | Attention, memory |
| Layer-specific | L1/V-VI | Cortical processing modulation |
| Receptor Type | Location | Effect |
|---|---|---|
| M1 (mAChR) | Pyramidal neurons | Excitatory, plasticity |
| M2 (mAChR) | Interneurons | Disinhibition |
| nAChR (α4β2) | Pyramidal neurons | Fast excitation |
| nAChR (α7) | Pyramidal, interneurons | Calcium influx, plasticity |
The NBM shows severe and early degeneration in AD:
The loss of NBM neurons leads to:
| Cholinergic Marker | Clinical Correlation |
|---|---|
| NBM neuron loss | Memory impairment severity |
| Cortical ACh reduction | Attention deficits |
| ChAT activity | Cognitive test scores |
| Drug | Dose | Mechanism | Side Effects |
|---|---|---|---|
| Donepezil | 5-23 mg/day | AChE inhibition | Nausea, insomnia |
| Rivastigmine | 1.5-12 mg/day | AChE/BChE inhibition | GI symptoms |
| Galantamine | 8-24 mg/day | AChE + allosteric nicotinic modulation | GI symptoms |
| Target | Approach | Status |
|---|---|---|
| M1 agonists | Selective muscarinic activation | Preclinical |
| α7 nAChR agonists | Nicotinic modulation | Phase II/III |
| BACE inhibitors | Reduce Aβ production | Halted (side effects) |
| TREM2 modulators | Microglial function | Preclinical |
The study of Nucleus Basalis Of Meynert Cholinergic Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol. 1983 ↩︎
Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science. 1983 ↩︎